Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Jonathon Myers
Study ID
NCT07228221
Phase
PHASE4
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • iStent infinite trabecular micro-bypass system model iS3 — DEVICE
    surgery perfomed using the iStent infinite trabecular micro-bypass system model iS3
  • iDose TR (Travoprost intracameral Implant) 75mcg — DRUG
    surgery performed using the iDose TR (Travoprost intracameral Implant) 75mcg

Study Details

The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.

Key Dates

Start date
Jan 5, 2026
Status verified
Nov 2025
Primary completion
Aug 30, 2031
Completion
Dec 31, 2031

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Surgery for patients with medically uncontrolled POAG
    surgery using combined minimally invasive surgical iStent infinite trabecular micro-bypass systme model iS3 and drug depot iDose TR (Travoprost Intracameral Implant) 75mcg

Primary Outcome Measure

IOP reduction from baseline [ Time Frame: Diurnal IOP reduction from baseline at 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Wills Eye Hosital Glaucoma Dept.PhiladelphiaPennsylvania19107
Meskerem Divers
(215)825-4712
Jeanne Molineaux, COA
(215)825-4713
Dilru Amarasekera, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Philadelphia, PA

By condition
By specialty

Related Studies